Claritev partners with iO Health to bring AI platform to MENA

MCLEAN, Va. & DUBAI - Claritev Corporation (NYSE:CTEV) announced Wednesday a strategic agreement with iO Health-FZE to deliver the Optima AI platform across the Middle East and North Africa (MENA) region.

Under the agreement, Claritev has secured exclusive rights to license, integrate, and resell iO Health’s AI-powered solution in the MENA region. The Optima AI platform is designed to help healthcare providers streamline financial and administrative processes, reduce claim denials, and improve financial outcomes. According to InvestingPro data, while Claritev has demonstrated strong market performance with a 419% return over the past year, analysts anticipate continued challenges in achieving profitability this year.

The partnership aims to integrate Optima AI into Claritev’s existing suite of products to enable hospitals, clinics, and payors to enhance claims management efficiency and decision-making through advanced analytics.

"Together with iO Health, we are bringing cutting-edge AI technology to healthcare providers and payors in MENA, with the goal of helping them improve financial health while reducing administrative burden," said Travis Dalton, President & CEO of Claritev.

Dr. Haidar Al Yousuf, CEO of iO Health, stated that the collaboration aims to "empower stakeholders to recover revenue faster, reduce operational inefficiencies, and ultimately create a smarter, more patient-centric healthcare ecosystem."

According to the press release, iO Health’s proprietary cognitive AI currently processes and optimizes insights from more than 32 million patient records across the MENA region.

Claritev, formerly known as MultiPlan, provides technology-enabled solutions and services to more than 700 healthcare payors, over 100,000 employers, 60 million consumers, and 1.4 million contracted providers. The company generates substantial EBITDA of $517.6 million, though InvestingPro analysis indicates it operates with a significant debt burden, with a debt-to-capital ratio of 0.84. For detailed insights and additional ProTips about Claritev’s financial health, investors can access the comprehensive Pro Research Report available on InvestingPro.

The companies will work together on implementation, integration, and ongoing support for healthcare organizations adopting the technology across the region. Based on InvestingPro’s Fair Value analysis, Claritev’s stock currently appears to be trading above its intrinsic value, suggesting investors might want to carefully evaluate entry points. Discover more overvalued stocks at Investing.com’s Most Overvalued Stocks list.

In other recent news, Claritev Corp reported a 3.5% increase in revenue for the second quarter of 2025, totaling $241.6 million. The company has adjusted its full-year revenue guidance, projecting a flat to 2% increase. Piper Sandler raised its price target for Claritev to $86 from $44, maintaining an Overweight rating, following what it described as a "beat and raise" in the company’s recent quarterly results. In leadership changes, Claritev named Brock Albinson as Senior Vice President and Chief Accounting Officer, succeeding Gerald Kozel. Albinson brings experience from his previous roles at Automatic Data Processing, Inc. and PricewaterhouseCoopers. The company has also been focusing on new product launches and operational adjustments, emphasizing AI initiatives and cost reductions. These developments reflect Claritev’s ongoing strategic shifts and financial performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.